已收盘 02-13 16:00:00 美东时间
-0.460
-0.56%
BTIG analyst Julian Harrison reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $82 price target.
2025-10-28 17:23
-每日资讯- 1、康为世纪收购昊为泰少数股东股权并完成全资控股 江苏康为世纪生物科技股份有限公司拟以1,788.50万元收购控股子公司上海昊为泰生物科技有限公...
2025-10-14 20:42
炒股就看金麒麟分析师研报,权威,专业,及时,全面,助您挖掘潜力主题机会! (来源:研报虎) 1.创新药出海是长期趋势,外部环境变化影响有限 根据医药...
2025-10-12 23:07
(来源:银柿财经) Icotrokinra是一款潜在“first-in-class”的靶向口服多肽,能够选择性阻断IL-23受体(IL-23R)。 据药明康...
2025-07-22 09:22
Top Wall Street analysts changed their outlook on these top names. For a comple...
2025-03-11 21:12
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints.
2025-03-10 22:04
Truist Securities analyst Srikripa Devarakonda initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $60.
2024-09-09 21:47